Transcatheter aortic-valve replacement with the self-expanding valve Portico in low-risk patients

Abstract Background In the past years, transcatheter aortic-valve replacement (TAVR) has risen as a feasible and safe option for patients with aortic stenosis, been now an of treatment in low-risk (Euroscore II <4%) over 75 years.1 Evidence this self-expandable supraanular bioprothesis Evolut have widely proven to be no inferior surgical valve replacement.2 Nevertheless, experience annular prothesis Portico available population is scarce. Purpose We present our early population. Methods retrospectively studied 219 symptomatic who underwent TAVR procedure valves between 2018 2021. Assessment included echocardiogram, immediate 30-day follow-up, well last clinical visit follow-up. 92 subjects received prothesis. Our reference group was suprannular (n=127), already validated trials.2 Results The mean age 79 43.4% were women, all at low risk (2.2 [1.6; 3.0]). No significant differences could appreciated baseline demographics echocardiographic characteristics except body mass index (BMI), which higher (p<0.001) (Table). Procedure length similar, particular need predilation according recommendations. Both had similar rates intraprocedural atrioventricular block, bleeding, vascular complications, stroke, new onset atrial fibrillation. Mean gradients before discharge lower than group, residual regurgitation almost inexistent both groups (Table 1). At follow up, incidence major adverse cardiac events among (p=0.6) (Figure 1), permanent pacemaker implantation, heart failure admission, bleeding o complication Conclusion Annular alternative AS undergo procedure. Funding Acknowledgement Type funding sources: None.